Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging.The earliest origins of ADNI lie in the groundbreaking discovery that antibodies targeting amyloid can remove amyloid beta (Aβ) plaques, sparking the advent of immunotherapy for Alzheimer's disease (AD). 1 At the same time, the importance of imaging and fluid biomarkers, particularly cerebrospinal fluid (CSF), in AD diagnosis gained recognition.ADNI was established in 2004 to validate and optimize biomarkers for AD clinical trials and freely share all the generated data with the scientific community without any restrictions.Since then, ADNI has evolved through five sequential phases incorporating advancements in the field and contributing to significant breakthroughs such as standardizing and validating Aβ and tau positron emission tomography (PET) imaging and CSF biomarkers.2-4 Moreover, ADNI data informed the design of clinical trials for aducanumab, 5 lecanemab, 6 donanemab, 7 solanezumab, 8 verubecestat, 9 crenezumab, 10 and gantenerumab, 11 facilitating the introduction of disease-modifying treatments into clinical practice.ADNI's open data sharing has led to over 6000 peer-reviewed publications, further highlighting the impact of the study.Furthermore, ADNI's approach to conducting longitudinal observational studies and openly sharing data served as a model for similar initiatives globally, leading to the creation of consortia like the Parkinson's Progression Markers Initiative (PPMI), 12 Japanese ADNI, 13 European ADNI, 14 Korean Brain Aging Study (KBASE), 15,16 China ADNI, 17 and South American initiatives.18 The following projects were also modeled on ADNI: the Dominantly Inherited Alzheimer Network (DIAN) studies, 19 Alzheimer's Disease Research Center Consortium for Clarity in Alzheimer's Disease and Related Dementias Research Through Imaging (CLARiTI), 20 Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), 21 Australian Imaging Biomarker & Lifestyle Flagship Study of Ageing (AIBL), 22 Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects Longitudinal Frontotemporal Lobar Degeneration (ALLFTD), 23 Diverse Vascular Contributions to Cognitive Impairment and Dementia (VCID), 24 and Biomarkers for Vascular Contr

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. ADNI was established to validate and optimize biomarkers for Alzheimer's clinical trials and shares its data openly, contributing to standardized Aβ and tau PET imaging and CSF biomarkers. ADNI data informed the design of trials for several drugs including aducanumab, lecanemab and donanemab, helping to bring disease-modifying treatments into clinical practice.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Okonkwo, O. C., Mindt, M. R., Weiner, M. W., & Alzheimer's Disease Neuroimaging Initiative. (2025). Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14186

Vancouver

Okonkwo OC, Mindt MR, Weiner MW, Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14186. PMID: 39760440.

BibTeX

@article{okonkwo2025-39760440,
  author  = {Okonkwo, Ozioma C. and Mindt, Mónica Rivera and Weiner, Michael Walter and {Alzheimer's Disease Neuroimaging Initiative}},
  title   = {{Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14186},
  pmid    = {39760440},
  url     = {https://doi.org/10.1002/alz.14186}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

ADNI was established to validate and optimize biomarkers for Alzheimer's clinical trials and shares its data openly, contributing to standardized Aβ and tau PET imaging and CSF biomarkers. ADNI data informed the design of trials for several drugs including aducanumab, lecanemab and donanemab, helping to bring disease-modifying treatments into clinical practice.

Study details

How this study scored 51/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 49 of the 96 points it could be judged on, which is 51 of 100. Total 51 of 100.49 of the 96 points we could judge = 51 of 100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 8 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.7 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 5.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39760440)
Free to read 2 / 2 Free to read
Points 49 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100.
Total 51 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →